Difference between revisions of "Part:BBa K4165152"
Line 18: Line 18:
 
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
 
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
 
   
 
   
−
ISAL1 is modeled by AlphaFold2, Apptest, ITASSER, best model obtained from Apptest.
+
ISAD1 is modeled by AlphaFold2, Apptest, ITASSER, best model obtained from Apptest.
  
  

Revision as of 18:04, 5 October 2022


ISAD1 Peptide

Tau binding peptide targeting the PHF seed of Tau


Usage and Biology

ISAD1 peptide with amino acid sequence of SVFKLSLTDAAS. It acts as an inhibitor for wild type full length tau aggregation.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry Lab

Modeling

ISAD1 is modeled by AlphaFold2, Apptest, ITASSER, best model obtained from Apptest. 



                            Figure 1.: Predicted 3D structure of Synthetic peptide ISAD1.


Table 1: Quality assessment parameters of ISAD1 model.


References

1. Aillaud, I., Kaniyappan, S., Chandupatla, R. R., Ramirez, L. M., Alkhashrom, S., Eichler, J., ... & Funke, S. A. (2022). A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro. Alzheimer's research & therapy, 14(1), 1-19.